Open AccessReduced graphene oxide‐based electrochemically stimulated method for temozolomide delivery
Author(s) -
Reddy Sathish,
Song Li,
Zhao Yuyuan,
Zhao Rong,
Wu Dongni,
He Liumin,
Ramakrishana Seeram
Publication year - 2018
Publication title -
medical devices & sensors
Language(s) - English
Resource type - Journals
ISSN - 2573-802X
DOI - 10.1002/mds3.10014
Subject(s) - temozolomide , graphene , drug delivery , drug , electrochemistry , oxide , materials science , nanotechnology , controlled release , biomedical engineering , pharmacology , chemistry , medicine , electrode , glioma , cancer research , metallurgy
The controlled release of drug molecules to a specific brain tumour's tissue has been recognized as one of the most demanding researches for treatment of brain cancer, because it helps to avoid the side effects from systemic drug delivery techniques. In the present work, described an electrochemically controlled drug delivery performed with a reduced graphene oxide (rGO)‐drug composite. The rGO was loaded with a temozolomide ( TMZ ) molecule ( rGO ‐ TMZ ) exhibits electrochemical oxidation and reduction peak in 0.1 M phosphate buffer solution ( pH 7.4). In response to be electrochemical potential, the rGO ‐ TMZ composite releases TMZ drug, and TMZ drug dosage that can be adjusted by altering the electrochemical potential with time. Upon application of an electrochemical potential pulse (0.8 V) for 20 min duration, up to 83% of TMZ was released into citrate buffer solution at pH 5.0. In vitro, cell culture experiments demonstrate that the released TMZ drug retains its bioactivity. The electrochemically controlled rGO‐ TMZ composite drug delivery platform makes it an exciting candidate for on‐demand drug delivery for effective treatment of brain cancer.